je.st
news
Impact of Nautilus on Biotech and Pharmaceutical Patents
2015-11-16 21:13:08| Biotech - Topix.net
In Nautilus, Inc. v. Biosig Instruments, Inc. , 134 S. Ct. 2120 , the Supreme Court rejected the Federal Circuit's "insolubly ambiguous" standard for determining whether a patent claim meets the definiteness requirement under 35 U.S.C. 112, 2, and held that "a patent is invalid for indefiniteness if its claims, read in light of the specification delineating the patent, and the prosecution history, fail to inform, with reasonable certainty, those skilled in the art about the scope of the invention."
Tags: impact
patents
pharmaceutical
biotech
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||
|
|||